

RESEARCH ARTICLE

Open Access

# Simple isatin derivatives as free radical scavengers: Synthesis, biological evaluation and structure-activity relationship

Gang Chen<sup>1</sup>, Ye Wang<sup>2</sup>, Xiaojiang Hao<sup>2\*</sup>, Shuzhen Mu<sup>2</sup> and Qianyun Sun<sup>2</sup>

## Abstract

To develop more potent small molecules with enhanced free radical scavenger properties, a series of *N*-substituted isatin derivatives was synthesized, and the cytoprotective effect on the apoptosis of PC12 cells induced by H<sub>2</sub>O<sub>2</sub> was screened. All these compounds were found to be active, and *N*-ethyl isatin was found with the most potent activity of 69.7% protective effect on PC12 cells. Structure-activity relationship analyses showed the bioactivity of *N*-alkyl isatins decline as the increasing of the chain of the alkyl group, furthermore odd-even effect was found in the activity, which is interesting for further investigation.

## Background

Oxidative stress has been implicated as a major role in the onset and progression of a vast variety of clinical abnormalities including neurodegenerative disorders. Free radicals play important roles in many physiological and pathological conditions [1]. In general, the generation and scavenging of oxygen free radicals is balanced and any imbalance or excessive amounts of active radicals may contribute to disease development. It has been found that free radical reactions can produce deleterious modifications in membranes, proteins, enzymes, and DNA [2], increasing the risk of diseases such as cancer [3], Alzheimer's [4], Parkinson's [5], angiocardopathy [6], arthritis [7], asthma [8], diabetes [9], and degenerative eye disease [10]. Therefore, it is important to find effective scavengers of free radicals for prevention and treatment of such disorders.

Isatin is an endogenous indole present in mammalian tissues and fluids [11]. The substance was initially discovered as a component of endogenous monoamine oxidase (MAO) inhibitory activity, tribulin, and subsequently identified as a selective inhibitor of MAO B [12]. Further investigations have shown that isatin acts as an antagonist of both atrial natriuretic peptide-stimulated and nitric oxide-stimulated guanylate cyclase

activity [13-15]. Isatin has a distinct and discontinuous distribution in rat brain and other tissues; the highest concentrations in the brain are found in the hippocampus and cerebellum [10]. Many Isatin derivatives, such as isatin hydrazono, isatin Mannich bases, isatin based spiroazetidinones and 3-(methylene)indolin-2-ones, have also been reported to possess neuroprotection activity [16-19].

To develop more potent small molecules with enhanced free radical scavenger properties, a series of *N*-substituted isatin derivatives was synthesized by substitution reactions (as shown in Scheme 1), and the cytoprotective effect on the apoptosis of PC12 cells induced by H<sub>2</sub>O<sub>2</sub> was screened.

## Results and Discussion


### Chemistry

The *N*-substituted isatin derivatives were synthesized by reactions of substitution reaction. The reaction between isatin and haloalkane has been reported being carried out in the presence of NaOEt using EtOH as solvent or in the presence of NaH using DMF as solvent [16]. The reactants and the solvents involved in the reactions must be anhydrous. To develop a simple method to synthesize *N*-substituted isatin derivatives, we firstly screened the effect of the base and solvent on the yield of the reaction of isatin and bromoethane (C<sub>2</sub>H<sub>5</sub>Br), and the results was shown in Table 1.

\* Correspondence: haoxj@mail.kib.ac.cn

<sup>2</sup>Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550002, PR China

Full list of author information is available at the end of the article



In this reaction, the protons transfers from N-H (a Brösted acid) to a Brösted or Lewis base via the hydrogen-bonded covalent and ionic complexes [20], producing the isatin anion which is the nucleophilic reactant to the halohydrocarbon. Higher solvent polarity can promote the proton-transfer equilibrium and leads to the higher yield [20]. From this table, it can be found that  $K_2CO_3$ -DMF system was an effective promotion for this reaction and other base-solvent systems were not effective with the yield no more than 60%. The possible reason might be that weak base can not help the proton transfer at the beginning effectively, but the too strong bases will lead to the substitution reaction between bromoethane and  $OH^-$ . DMF exhibits the highest yield of 89% with  $K_2CO_3$  for its highest solvent polarity, so the  $K_2CO_3$ -DMF was selected as the reactant reaction system in the following synthesis, and the results were shown in Table 2.

### Bioactivity

The chemical modification of lead compound **1**, focusing on the *N*-substituent, was carried out to further improve the free scavenging ability. A series of new *N*-substituted isatin derivatives (compounds **2-12**) was synthesized. The free radical scavenging properties of these derivatives were evaluated to elucidate structure-activity relationships. The protective effect on the apoptosis of PC12 cells induced by  $H_2O_2$  by free radical scavenging of these compounds against  $H_2O_2$  were evaluated by cell survival assay in PC12 cells using a reported method [21]. The results were given in Table 3.

From the table, we can find almost all of the compounds showed potent activity at the condensation of 2

**Table 1** The substitution reaction between isatin and bromoethane

No.	Solvent	Base	Time (h)	Yield (%)
1	DMF	$Na_2CO_3$	24	33
2	DMF	$K_2CO_3$	12	89
3	DMF	NaOH	12	40
4	DMF	KOH	12	41
5	DMF	TEA	24	60
6	MeOH	$K_2CO_3$	24	12
7	THF	$K_2CO_3$	24	25
8	DCM	$K_2CO_3$	24	19
9	Acetonitrile	$K_2CO_3$	24	15

**Table 2** Synthesis of *N*-substituted isatin derivatives

Compound	R	Time (h)	Yield (%)
1	H	–	–
2	$CH_3$	4	87
3	$C_2H_5$	12	89
4	$(CH_2)_2CH_3$	12	89
5	$(CH_2)_3CH_3$	24	93
6	$(CH_2)_4CH_3$	24	90
7	$(CH_2)_5CH_3$	24	95
8	$CH_2CH=CH_2$	12	93
9	$CH_2C_6H_5$	12	90
10	$CH_2COOC_2H_5$	12	93
11	$C_2H_4Cl$	24	79
12	$C_2H_4Br$	24	83

$\mu g/ml$ , which were more effective than VE ( $\pm$ )  $\alpha$ -Tocopherol with the percentage of 22.5%). There is a noteworthy phenomenon that the activities of all compounds at the condensation of 2  $\mu g/ml$  are more potent than that at the condensation of 20  $\mu g/ml$ , and the mechanism will be interesting for the further investigation. Compound **3** and **8** exhibited the most potent activity with the protective effect of 69.8% and 69.5% at the condensation of 2  $\mu g/ml$  respectively, which are more potent than that at the condensation of 20  $\mu g/ml$ .

Almost all of these compounds were weakly cytotoxic to PC12 cells at the concentrations of 2-20  $\mu g/ml$  except compound 11 and 12. Almost all compounds are cytotoxic to PC12 cells at the concentrations of 200  $\mu g/ml$ , the PC12 cells inhibitory effects are more than 40%. Based on the factors, we can conclude the addition of halogenous atom in the substituents (compound **11** and

**Table 3** Inhibitory and protective effects of *N*-substituted isatin derivatives

Compound	Inhibitory effect/% <sup>a</sup>			Protective effect/% <sup>b</sup>		
	200 $\mu g/ml$	20 $\mu g/ml$	2 $\mu g/ml$	200 $\mu g/ml$	20 $\mu g/ml$	2 $\mu g/ml$
1	92.0	0.0	2.6	-	20.1	40.4
2	60.6	2.7	5.0	-	31.4	50.9
3	45.6	0.4	7.0	-	38.2	69.8
4	43.0	3.3	0.0	-	10.1	39.7
5	53.3	0.0	0.0	-	30.0	60.8
6	51.9	0.0	0.0	-	8.2	24.1
7	50.4	0.0	0.0	0	15.5	20.9
8	54.0	2.1	0.0	-	14.8	69.5
9	63.1	0.0	0.0	-	9.3	51.3
10	67.9	0.0	5.3	-	46.6	54.5
11	63.5	20.5	5.6	-	0	25.1
12	61.6	24.1	12.3	-	0	62.1
VE			<b>0.0</b>			<b>22.5</b>

a) Inhibition of PC12 cell growth; b) protective effect on the apoptosis of PC12 cells induced by  $H_2O_2$ .

12) enhance the cytotoxicity at the concentrations of 2-20  $\mu\text{g/ml}$ .

The substitution reaction between isatin and halo-hydrocarbon (C1 to C6) gave compounds 2-7, which provided the appropriate material for the structure-activity relationship analyses. The cytoprotective activities of *N*-substituted isatin derivatives with the alkyl group containing one to six carbon atoms were shown in Figure 1. The activity approximately declines as the increase of the chain of the alkyl group. With a further analysis, it was found that there was a clear odd-even effect in these activities. The activities of *N*-substituted isatin derivatives with odd carbon atoms alkyl group (one, three and five carbon atoms, corresponding compound 2, 4 and 6, marked with solid pillars in Figure 1) decline as the chain of the alkyl group increases, and the same regulation can be found in the activities of the *N*-substituted isatin derivatives with even carbon atoms alkyl group (two, four and six carbon atoms, corresponding compound 3, 5 and 7, marked with virtual pillars in Figure 1). This regulation exhibits both under the condensation of 2  $\mu\text{g/ml}$  and 20  $\mu\text{g/ml}$ , and the activities of *N*-substituted isatin derivatives with even carbon atoms alkyl group are more potent than the that of *N*-substituted isatin derivatives with parallel odd carbon atoms alkyl group. Besides, by the structure-activity relationship analyses, it was found that the unsaturated bond of the substituent (compound 8-10) can improve the activity compared with the other substituents with similar carbon atoms.

## Experimental


All starting materials and solvents (A.R. grade) were commercially available and were used without further purification. NMR spectra were recorded using a Bruker Drx-400 spectrometer operating at 400 MHz for  $^1\text{H}$ . Mass spectra were recorded on a Micromass Platform spectrometer using a direct-inlet system operating in the electron impact (EI) mode at 75 eV. Elemental analyses were obtained using a Carlo Erba 1106 elemental analyzer.

### General synthesis of *N*-alkyl substituted isatin derivatives

Isatin (1 mmol) and halo-hydrocarbon (1.2 mmol) were dissolved in DMF (20 ml), and 3 mmol anhydrous  $\text{K}_2\text{CO}_3$  was added. The mixture was stirred under room temperature until the disappearance of isatin, as evidenced by thin-layer chromatography. The solvent was removed in vacuo and the residue was separated by column chromatography (silica gel, petroleum ether/ethyl acetate = 20:1), giving *N*-alkyl substituted isatin compound (compound 2-12).

**1-Methylindoline-2,3-dione (Compound 2)**  $^1\text{H-NMR}$  ( $\text{D}_6\text{-DMSO}$ , 400 MHz): 7.66 (1 H, td,  $J = 1.2, 7.6$  Hz), 7.52 (1 H, d,  $J = 7.6$  Hz), 7.12 (2 H, t,  $J = 7.6$  Hz), 3.12 (3 H, s); MS (EI)  $m/z$ : 161 ( $\text{M}^+$ ); Anal. Found: C, 67.01; H, 4.40; N, 8.66 (%). Calc. for ( $\text{C}_9\text{H}_7\text{NO}_2$ ): C, 67.07; H, 4.38; N, 8.69 (%).

**1-Ethylindoline-2,3-dione (Compound 3)**  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 400 MHz): 7.57 (2 H, m), 7.09 (1 H, t,  $J = 7.6$  Hz), 6.89 (1 H, d,  $J = 7.6$  Hz), 3.76 (2 H, q,  $J = 7.6$  Hz), 1.29 (3 H, t,  $J = 7.6$  Hz); MS (EI)  $m/z$ : 175 ( $\text{M}^+$ ); Anal.



**Figure 1** The cytoprotective activities of *N*-substituted isatin derivatives with the alkyl group containing 1-6 carbon atoms (The corresponding compounds are compounds 2-7).

Found: C, 68.59; H, 5.22; N, 8.01 (%). Calc. for (C<sub>10</sub>H<sub>9</sub>NO<sub>2</sub>): C, 68.56; H, 5.18; N, 8.00 (%).

**1-Propylindoline-2,3-dione (Compound 4)** <sup>1</sup>H-NMR (D<sub>6</sub>-DMSO, 400 MHz): 7.58 (1 H, d, *J* = 6.8 Hz), 7.55 (1 H, t, *J* = 7.6 Hz), 7.09 (1 H, t, *J* = 7.6 Hz), 6.88 (1 H, d, *J* = 8 Hz), 3.67 (2 H, t, *J* = 7.2 Hz), 1.72 (2 H, m, *J* = 7.2-7.6 Hz), 0.98 (3 H, t, *J* = 7.6 Hz); MS (EI) *m/z*: 189 (M<sup>+</sup>); Anal. Found: C, 69.88; H, 5.89; N, 7.35 (%). Calc. for (C<sub>11</sub>H<sub>11</sub>NO<sub>2</sub>): C, 69.83; H, 5.86; N, 7.40 (%).

**1-Butylindoline-2,3-dione (Compound 5)** <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz) δ: 7.60 (2 H, m), 7.12 (1 H, t, *J* = 7.6 Hz), 6.91 (1 H, d, *J* = 8.4 Hz), 3.73 (2 H, t, *J* = 7.6 Hz), 1.69 (2 H, m), 1.42 (2 H, m), 0.98 (3 H, t, *J* = 7.2 Hz); MS (EI) *m/z*: 203 (M<sup>+</sup>); Anal. Found: C, 70.90; H, 6.59; N, 6.90 (%). Calc. for (C<sub>12</sub>H<sub>13</sub>NO<sub>2</sub>): C, 70.92; H, 6.54; N, 6.89 (%).

**1-Pentylindoline-2,3-dione (Compound 6)** <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz) δ: 7.60 (2 H, m), 7.12 (1 H, t, *J* = 7.6 Hz), 6.91 (1 H, d, *J* = 8.0 Hz), 3.72 (2 H, t, *J* = 7.6 Hz), 1.71 (2 H, m), 1.37 (4 H, m), 0.91 (3 H, t, *J* = 6.8 Hz); MS (EI) *m/z*: 217 (M<sup>+</sup>); Anal. Found: C, 71.88; H, 7.00; N, 6.44 (%). Calc. for (C<sub>13</sub>H<sub>15</sub>NO<sub>2</sub>): C, 71.87; H, 6.96; N, 6.45 (%).

**1-Hexylindoline-2,3-dione (Compound 7)** <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz) δ: 7.60 (2 H, m), 7.11 (1 H, t, *J* = 7.6 Hz), 6.90 (1 H, d, *J* = 7.6 Hz), 3.72 (2 H, t, *J* = 7.6 Hz), 1.70 (2 H, m), 1.31-1.38 (6 H, m), 0.89 (3 H, t, *J* = 6.4 Hz); MS (EI) *m/z*: 231 (M<sup>+</sup>); Anal. Found: C, 72.72; H, 7.40; N, 6.01 (%). Calc. for (C<sub>14</sub>H<sub>17</sub>NO<sub>2</sub>): C, 72.70; H, 7.41; N, 6.06 (%).

**1-Allylindoline-2,3-dione (Compound 8)** <sup>1</sup>H-NMR (D<sub>6</sub>-DMSO, 400 MHz): 7.63 (1 H, t, *J* = 7.6 Hz), 7.55 (1 H, d, *J* = 7.2 Hz), 7.12 (1 H, t, *J* = 7.6 Hz), 7.04 (1 H, d, *J* = 7.6 Hz), 5.84 (1 H, m, *J* = 5.2-5.6 Hz), 5.32 (1 H, d, *J* = 17.2 Hz), 5.18 (1 H, d, *J* = 10.4 Hz), 4.30 (2 H, d, *J* = 4.8 Hz); MS (EI) *m/z*: 187 (M<sup>+</sup>); Anal. Found: C, 70.60; H, 4.84; N, 7.49 (%). Calc. for (C<sub>11</sub>H<sub>9</sub>NO<sub>2</sub>): C, 70.58; H, 4.85; N, 7.48 (%).

**1-Benzylindoline-2,3-dione (Compound 9)** <sup>1</sup>H-NMR (D<sub>6</sub>-DMSO, 400 MHz) δ: 7.56 (2 H, m), 7.42 (2 H, d, *J* = 7.6 Hz), 7.30 (2 H, t, *J* = 7.6 Hz), 7.27 (1 H, m), 7.10 (1 H, t, *J* = 7.6 Hz), 6.96 (1 H, m), 4.90 (2 H, s); MS (EI) *m/z*: 233 (M<sup>+</sup>); Anal. Found: C, 75.99; H, 4.65; N, 5.92 (%). Calc. for (C<sub>15</sub>H<sub>11</sub>NO<sub>2</sub>): C, 75.94; H, 4.67; N, 5.90 (%).

**Ethyl 2-(2,3-dioxindolin-1-yl)acetate (Compound 10)** <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz) δ: 7.62 (1 H, d, *J* = 7.6 Hz), 7.57 (1 H, t, *J* = 7.6 Hz), 7.14 (1 H, t, *J* = 7.6 Hz), 6.77 (1 H, d, *J* = 7.6 Hz), 4.47 (2 H, s), 4.22 (2 H, q, *J* = 7.2 Hz), 1.26 (3 H, t, *J* = 7.2 Hz); MS (EI) *m/z*: 233 (M<sup>+</sup>); Anal. Found: C, 61.84; H, 4.72; N, 6.00 (%). Calc. for (C<sub>12</sub>H<sub>11</sub>NO<sub>4</sub>): C, 61.80; H, 4.75; N, 6.01 (%).

**1-(2-Chloroethyl)indoline-2,3-dione (Compound 11)** <sup>1</sup>H-NMR (D<sub>6</sub>-DMSO, 400 MHz) δ: 7.67 (1 H, td, *J* = 8,

1.2 Hz), 7.56 (1 H, dd, *J* = 7.6, 1.2 Hz), 7.29 (1 H, d, *J* = 8.0 Hz), 7.14 (1 H, dd, *J* = 7.6, 0.8 Hz), 4.10 (2 H, t, *J* = 6.4 Hz), 3.70 (2 H, t, *J* = 6.4 Hz); MS (EI) *m/z*: 211 (M<sup>+</sup>); Anal. Found: C, 58.86; H, 3.99; N, 13.70 (%). Calc. for (C<sub>10</sub>H<sub>8</sub>ClNO<sub>2</sub>): C, 58.82; H, 3.95; N, 13.72 (%).

**1-(2-Bromoethyl)indoline-2,3-dione (Compound 12)** <sup>1</sup>H-NMR (D<sub>6</sub>-DMSO, 400 MHz) δ: 7.67 (1 H, td, *J* = 8, 1.2 Hz), 7.57 (1 H, dd, *J* = 7.6, 1.2 Hz), 7.29 (1 H, d, *J* = 8.0 Hz), 7.14 (1 H, dd, *J* = 7.6, 0.8 Hz), 4.11 (2 H, t, *J* = 6.4 Hz), 3.71 (2 H, t, *J* = 6.4 Hz); MS (EI) *m/z*: 254 (M<sup>+</sup>); Anal. Found: C, 47.31; H, 3.19; N, 5.50 (%). Calc. for (C<sub>10</sub>H<sub>8</sub>BrNO<sub>2</sub>): C, 47.27; H, 3.17; N, 5.51 (%).

#### Acknowledgements

This work was financially supported by the grant from Scientific Research Program Funded by Shaanxi Provincial Education Department (Program No.11JK0560).

#### Author details

<sup>1</sup>College of Chemistry and Chemical Engineering, Xi'an Shiyu University, Xi'an, Shaanxi, 710065, PR China. <sup>2</sup>Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550002, PR China.

#### Authors' contributions

GC has formulated the research idea and prepared the manuscript draft version, YW prepared the manuscript for submission and coordinated further formalities, SM and QS carried out the chemical and biological studies, XH conceived of the study, participated in its design and coordination. All authors have read and approved the final manuscript.

#### Competing interests

The authors declare that they have no competing interests.

Received: 19 April 2011 Accepted: 1 July 2011 Published: 1 July 2011

#### References

1. Vendemiale G, Grattagliano I, Altomare E: An update on the role of free radicals and antioxidant defense in human disease. *Int J Clin Lab Res* 1999, **29**:49-55.
2. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. *Chem Biol Interact* 2006, **160**:1-40.
3. Cooke MS, Evans MD, Dizdaroğlu M, Lunec J: Oxidative DNA damage: mechanisms, mutation and disease. *FASEB J* 2003, **17**:1195-1214.
4. Richardson JS: Free radicals in the genesis of Alzheimer's disease. *Annals of the New York Academy of Sciences* 2006, **695**:73-76.
5. Olanow CW: An introduction to the free radical hypothesis in Parkinson's disease. *Ann Neurol* 1992, **32**:S2-S9.
6. Bankson DD, Kestin M, Rifai N: Role of free radicals in cancer and atherosclerosis. *Clin Lab Med* 1993, **13**:463-480.
7. Jaswal S, Mehta HC, Sood AK, Kaur J: Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. *Clin Chim Acta* 2003, **338**:123-129.
8. Mak JC, Chan YMM: Reactive oxidant species in asthma. *Curr Opin Pulm Med* 2006, **12**:7-11.
9. Shen SS, Nauduri D, Anders MW: Targeting antioxidants to mitochondria: A new therapeutic direction. *Biochim Biophys Acta* 2006, **1762**:256-265.
10. Glover V, Halket JM, Watkins PJ, Clow A, Goodwin BL, Sandler M: Isatin: Identity with the purified endogenous monoamine oxidase inhibitor tribulin. *J Neurochem* 1988, **51**:656-659.
11. Glover V, Reveley MA, Sandler M: A monoamine oxidase inhibitor in human urine. *Biochem Pharmacol* 1980, **29**:467-470.
12. Medvedev AE, Clow A, Sandler M, Glover V: Isatin: A link between natriuretic peptides and monoamines? *Biochem Pharmacol* 1996, **52**:385-391.

13. Medvedev AE, Bussygyna O, Pyatakova N, Glover V, Severina I: **Effect of isatin on nitric oxide-stimulated soluble guanylate cyclase from human platelets.** *Biochem Pharmacol* 2002, **63**:763-766.
14. Glover V, Bhattarya SK, Chakrabarti A, Sandler M: **The psychopharmacology of Isatin: A brief review.** *Stress Med* 1998, **14**:225-229.
15. Glover V, Medvedev A, Sandler M: **Isatin is a potent endogenous antagonist of guanylate cyclase-coupled atrial natriuretic peptide receptors.** *Life Sci* 1995, **57**:2073-2079.
16. Webber SE, Tikhe J, Worland ST, Fuhrman SA, Hendrickson TF, Matthews DA, Love RA, Patick AK, Meador JW, Ferre RA, Brown EL, DeLisle DM, Ford CE, Binford SL: **Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.** *J Med Chem* 1996, **39**(26):5072-5082.
17. Chen G, He HP, Ding J, Hao XJ: **Synthesis and antitumor activity evaluation of regioselective spiro [pyrrolidine-2, 3'-oxindole] compounds.** *Heterocycl Commun* 2009, **15**(5):355-360.
18. Chen G, Wang Y, Gao S, He HP, Li SL, Zhang JX, Ding J, Hao XJ: **Synthesis and bioactivity evaluation of 3-hydroxy-3-(phenylethynyl) indol-2-one analogues.** *J Heterocyclic Chem* 2009, **46**:217-220.
19. Chen G, Hao XJ, Sun QY, Ding J: **Rapid eco-friendly synthesis and bioactivities of 3-nitromethylene-1,3-dihydro-indol-2-one analogues.** *Chem Pap* 2010, **64**(5):673-677.
20. Reichardt C: **Solvent effects on Brösted acid/base equilibria.** *Solvent and solvent effect in organic chemistry, third edition* Weinheim, FRG: Wiley and Sons; 2003, 647-748.
21. Mosmann TJ: **Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.** *J Immunol Methods* 1983, **65**:55-63.

doi:10.1186/1752-153X-5-37

**Cite this article as:** Chen *et al.*: Simple isatin derivatives as free radical scavengers: Synthesis, biological evaluation and structure-activity relationship. *Chemistry Central Journal* 2011 **5**:37.

Publish with **ChemistryCentral** and every scientist can read your work free of charge

*“Open access provides opportunities to our colleagues in other parts of the globe, by allowing anyone to view the content free of charge.”*

W. Jeffery Hurst, The Hershey Company.

- available free of charge to the entire scientific community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
<http://www.chemistrycentral.com/manuscript/>

  
**ChemistryCentral**